The UK and US have forged a major trade agreement that will guarantee no tariffs on British drug exports entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the NHS. This pledge ensures that import taxes on these vital goods will remain at nothing for a duration of 36 months.
This agreement comes after previous statements to hike import taxes on branded drug imports, with potential rates discussed up to one hundred percent.
"This agreement between the UK strengthens the international landscape for cutting-edge drugs and introduces much-needed balance to transatlantic drug exports," an announcement said.
Trade Impact
Pharmaceuticals constitute one of the Britain's most significant goods shipped to the US, which is by far the primary destination for major British pharmaceutical firms.
Statistics reveal that in the year to the end of last September, the UK exported drugs valued at billions to the US. This amount made up 17.4% of all goods exports in that period.
"This deal safeguards employment, stimulates investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Detailed British Pledges
The pact involves several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. In the past, repayments were more than 20%.
Broader Context
This agreement follows a long-running tension between the drug companies and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by assertions that American patients were charged significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several large drug company projects in the UK have been delayed or scrapped, while substantial expansions have been pledged toward American operations.
One official acknowledged that the NHS had to spend more on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the past decade.
